Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Total Valuation
Nektar Therapeutics has a market cap or net worth of $2.07B. The enterprise value is $1.60B.
Market Cap$2.07B
Enterprise Value$1.60B
Share Statistics
Nektar Therapeutics has 27,979,520 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,979,520
Owned by Insiders5.11%
Owned by Institutions21.59%
Financial Efficiency
Nektar Therapeutics’s return on equity (ROE) is -1.83 and return on invested capital (ROIC) is -52.82%.
Return on Equity (ROE)-1.83
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-52.82%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee905.44K
Profits Per Employee-2.69M
Employee Count61
Asset Turnover0.20
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nektar Therapeutics is ―. Nektar Therapeutics’s PEG ratio is -0.36.
PE Ratio―
PS Ratio12.91
PB Ratio7.94
Price to Fair Value7.94
Price to FCF-3.42
Price to Operating Cash Flow-7.00
PEG Ratio-0.36
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 55.23M and earned -164.08M in profits. Earnings per share was -9.73.
Revenue55.23M
Gross Profit55.23M
Operating Income-130.77M
Pretax Income-164.21M
Net Income-164.08M
EBITDA-129.74M
Earnings Per Share (EPS)-9.73
Cash Flow
In the last 12 months, operating cash flow was -208.51M and capital expenditures -171.00K, giving a free cash flow of -208.68M billion.
Operating Cash Flow-208.51M
Free Cash Flow-208.68M
Free Cash Flow per Share-7.46
Dividends & Yields
Nektar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.78
52-Week Price Change429.40%
50-Day Moving Average53.64
200-Day Moving Average43.42
Relative Strength Index (RSI)61.64
Average Volume (3m)1.44M
Important Dates
Nektar Therapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Nektar Therapeutics as a current ratio of 4.97, with Debt / Equity ratio of 165.76%
Current Ratio4.97
Quick Ratio4.97
Debt to Market Cap0.12
Net Debt to EBITDA-1.03
Interest Coverage Ratio-4.99
Taxes
In the past 12 months, Nektar Therapeutics has paid -138.00K in taxes.
Income Tax-138.00K
Effective Tax Rate<0.01
Enterprise Valuation
Nektar Therapeutics EV to EBITDA ratio is -6.53, with an EV/FCF ratio of -4.06.
EV to Sales15.34
EV to EBITDA-6.53
EV to Free Cash Flow-4.06
EV to Operating Cash Flow-4.06
Balance Sheet
Nektar Therapeutics has $245.75M in cash and marketable securities with $148.91M in debt, giving a net cash position of $96.84M billion.
Cash & Marketable Securities$245.75M
Total Debt$148.91M
Net Cash$96.84M
Net Cash Per Share$3.46
Tangible Book Value Per Share$5.32
Margins
Gross margin is 99.30%, with operating margin of -236.77%, and net profit margin of -297.07%.
Gross Margin99.30%
Operating Margin-236.77%
Pretax Margin-297.32%
Net Profit Margin-297.07%
EBITDA Margin-234.91%
EBIT Margin-236.77%
Analyst Forecast
The average price target for Nektar Therapeutics is $126.48, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$126.48
Price Target Upside72.67% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-32.79%
EPS Growth Forecast36.87%